pheniramine

Trade name: Tripoton

Small moleculeapproved

Approved

Jul 1, 1948

Pheniramine is an antihistamine used to treat allergic conditions such as hay fever or urticaria. It is generally sold in combination with other medications, rather than as a stand-alone drug. Allergies are caused by an excessive type 1 hypersensitivity response of the body to allergens, mediated by inappropriate histamine signalling. By inhibiting the binding of histamine, antihistamines decrease the normal histamine response from cells, consequently decreasing allergic symptoms. Antihistamines such as pheniramine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. Antihistamines suppress the histamine-induced wheal (swelling) and flare (vasodilation) response by blocking the binding of histamine to its receptors on nerves, vascular smooth muscle, glandular cells, endothelium, and mast cells. They effectively exert competitive antagonism of histamine for H1-receptors. Pheniramine is marketed under the trade name Avil and Visine-A among others). — NCATS

Clinical trial activity

3 trials · 4 clinical orgs · 7 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
1

Earliest trial started Aug 1, 2011 (NCT01390961)

Timeline

1940s

  1. Jul 1, 1948

    Earliest FDA Approval

1990s

  1. Jun 8, 1994

    Bausch & Lomb — First NDA Organization

  2. Jun 8, 1994

    Alcon — NDA Secondary Org

  3. Jun 8, 1994

    Bausch & Lomb — NDA Secondary Org

  4. Jun 8, 1994

    Nestle — NDA Secondary Org

  5. Jun 8, 1994

    Bausch & Lomb — NDA Organization

  6. Jan 31, 1996

    Johnson and Johnson — NDA Secondary Org

2010s

  1. Sep 27, 2010

    Altair Therapeutics — Marketing Organization

  2. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

  3. Jan 24, 2013

    Akorn, Inc. — Marketing Organization

  4. Jan 24, 2013

    Rising Pharmaceuticals — Marketing Organization

Indications

Mechanism of action

Combination products

  • opcon-a

    with naphazoline

    Also known as naphcon-a, visine

Approval history

  • approvedJul 1, 1948

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCC(c1ccccc1)c1ccccn1
Mol. weight
240.35 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Over the Counter

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • avil ret
  • daneral-sa
  • feniramina
  • feniramina
  • pheniramine
  • pheniramine
  • pheniramine
  • pheniramine
  • pheniramine
  • pheniramine
  • pheniramine
  • pheniramine
  • pheniramine maleate
  • pheniramine maleate
  • pheniramine maleate
  • pheniramine maleate
  • pheniraminum
  • pheniraminum
  • propheniramine
  • propheniramine
  • propheniramine
  • propheniramine
  • propheniramine
  • propheniramine
  • prophenpyridamine
  • pyriton
  • trimeton
  • trimeton
  • tripoton

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02730364Phase 3Feb 1, 2017GlaxoSmithKline
NCT01533220Phase 3Jun 1, 2013EMS S/A
NCT01390961Phase 4Aug 1, 2011Allergan, Hom, Milton M., OD, FAAO
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AllerganFor profit1012011
EMS S/AFor profit1112013
GlaxoSmithKlineFor profit1112017
Hom, Milton M., OD, FAAOAcademic/Hospital1112011
4 organizations
Page 1 / 1

Marketing (9)

OrganizationOrg typeRelationshipDate
Akorn, Inc.For profitSYNJan 24, 2013
Akorn, Inc.For profitMKTGJan 24, 2013
AlconFor profitNDA2Jun 8, 1994
Altair TherapeuticsFor profitMKTGSep 27, 2010
Bausch & LombFor profitNDA2Jun 8, 1994
Bausch & LombFor profitNDAJun 8, 1994
Johnson and JohnsonFor profitNDA2Jan 31, 1996
NestleFor profitNDA2Jun 8, 1994
Rising PharmaceuticalsFor profitMKTGJan 24, 2013